ClearNote Health
About ClearNote Health
ClearNote Health develops non-invasive cancer detection tests based on an epigenomics platform that analyzes cell-free DNA to identify signals of cancer early, when treatment is most effective. The company focuses on cancers with high mortality rates and offers a range of tests and biopharma partnerships to support early detection and clinical validation. Headquartered around the United States, ClearNote Health emphasizes early cancer detection through liquid biopsy-based assays and strong clinical evidence.
Recent News
Cognition Raises $1 Billion to Scale Autonomous Software Engineering
ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection
The Week’s 10 Biggest Funding Rounds: Anthropic Dominates In An Otherwise Slower Week For Megarounds
Recent Deals
No recent deals for this company.